H. Terazaki et al., A novel compound heterozygote (FAP ATTR Arg104His/ ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels, BIOC BIOP R, 264(2), 1999, pp. 365-370
Citations number
38
Categorie Soggetti
Biochemistry & Biophysics
Journal title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
A 64-year-old Japanese male suffering from very slowly progressive amyloido
sis was studied by immunohistopathologic, mass spectrometric, and molecular
genetic methods. After confirming the immunoreactivity of transthyretin (T
TR) in the amyloid deposits using an anti-TTR polyclonal antibody, matrix-a
ssisted laser desorption ionization/time-of-flight-mass spectrometry (MALDI
/TOF-MS) was employed to look for the presence of variant TTR(s) in the ser
um. Two variant forms of TTR, one with a molecular weight 32 Da greater and
another with a molecular weight 19 Da less than that of normal TTR encoded
by the two respective alleles, were detected in this patient. Direct seque
nce analysis confirmed the presence of a double substitution: one at codon
30 from GTG (Val) to ATG; (Met) and the other at codon 104 from CGC (Arg) t
o CAC (His) in the two alleles, MALDI/TOF-MS of the parents of the proband
revealed that his father was a heterozygote of ATTR Arg104His and his mothe
r was a heterozygote of ATTR Val30Met, The total TTR and retinol binding pr
otein (RBP) concentrations in the serum samples of the proband were very hi
gh compared with those of FAP ATTR Val30Met patients and control subjects.
We report here a new compound heterozygote in the TTR gene with familial am
yloidotic polyneuropathy (FAP). (C) 1999 Academic Press.